Rhythm li­cens­es obe­si­ty drug for $100M; Gala­pa­gos teams up with Brid­Gene; In­sil­i­co’s new deal

Plus, news about Boehringer In­gel­heim, Mer­ck KGaA, Atai Life Sci­ences, Re­salis Ther­a­peu­tics, Portage Biotech, Sen­sei Bio­ther­a­peu­tics and ADC Ther­a­peu­tics:

Rhythm li­cens­es obe­si­ty drug for $100M: Rhythm Phar­ma­ceu­ti­cals will pay LG Chem $40 mil­lion in cash and $20 mil­lion in eq­ui­ty in a deal to li­cense the South Ko­re­an com­pa­ny’s LB54640, an oral small mol­e­cule MC4R ag­o­nist that is mov­ing in­to Phase II tri­als for hy­po­thal­a­m­ic obe­si­ty. LG Chem is set to re­ceive an ad­di­tion­al $40 mil­lion 18 months af­ter the deal clos­es, and it could po­ten­tial­ly re­ceive $205 mil­lion in reg­u­la­to­ry and sales mile­stones, as well as roy­al­ties. — Kather­ine Lewin

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER